ST638 |
| Katalog-Nr.GC11520 |
ST638 ist ein potenter Tyrosinkinase-Inhibitor mit einem IC50 von 370 nM.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 107761-24-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
ST638 is a tyrosine kinase inhibitor [1].
Tyrosine kinases are a family of protein kinases that phosphorylate the serine and threonine on other proteins. Phosphorylation of proteins by kinases has been involved in signal transduction and regulating cellular activity, such as cell division. Tyrosine kinases function in a variety of processes, such as mitogenesis, induction of mitosis, and transmembrane signaling [2].
In human platelets, preincubation with 50 μM of ST638 completely blocked the platelet aggregation induced with 0.05 unit/ml of thrombin. ST638 inhibited the increase of protein-tyrosine phosphorylation bands induced with thrombin in a dose-dependent manner. ST638 blocked the platelet aggregation and protein-tyrosine phosphorylation induced with thrombin in aspirin-treated platelets [1]. In terminal erythroid differentiation of mouse erythroleukemia (MEL) cells, ST638 effectively induced differentiation in a synergistic manner [3]. In rat and rabbit pulmonary artery cells, ST 638 (0.5 to 40 μmol/L) blocked IK in a dose-dependent manner [4].
References:
[1] Asahi M, Yanagi S, Ohta S, et al. Thrombin-induced human platelet aggregation is inhibited by protein-tyrosine kinase inhibitors, ST638 and genistein[J]. FEBS letters, 1992, 309(1): 10-14.
[2] Levitzki A, Gazit A. Tyrosine kinase inhibition: an approach to drug development[J]. Science, 1995, 267(5205): 1782.
[3] Watanabe T, Shiraishi T, Sasaki H, et al. Inhibitors for protein-tyrosine kinases, ST638 and genistein, induce differentiation of mouse erythroleukemia cells in a synergistic manner[J]. Experimental cell research, 1989, 183(2): 335-342.
[4] Smirnov S V, Aaronson P I. Inhibition of vascular smooth muscle cell K+ currents by tyrosine kinase inhibitors genistein and ST 638[J]. Circulation Research, 1995, 76(2): 310-316.
| Cas No. | 107761-24-0 | SDF | |
| Chemical Name | 2-cyano-3-[3-ethoxy-4-hydroxy-5-[(5-phenylthio)methyl]phenyl]-2-propenamide | ||
| Canonical SMILES | OC1=C(C=C(C=C(C(N)=O)C#N)C=C1OCC)CSC2=CC=CC=C2 | ||
| Formula | C19H18N2O3S | M.Wt | 354.4 |
| Löslichkeit | ≤30mg/ml in DMSO;50mg/ml in dimethyl formamide | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.8217 mL | 14.1084 mL | 28.2167 mL |
| 5 mM | 0.5643 mL | 2.8217 mL | 5.6433 mL |
| 10 mM | 0.2822 mL | 1.4108 mL | 2.8217 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 7 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *